glp 1 oral drug New GLP-1 Outperforms Semaglutide Market Overview: GLP-1 Agonists and

PsA Disease Activity Improves on GLP-1s A retrospective study presented at ACR Convergence 2025, led by researchers from the University of Toronto and NYU, followed 48 patients with psoriatic arthritis who started GLP-1 receptor agonists. The findings: Significant weight loss (35% of patients lost 510% of body weight

The FDA approved it in 2012 as an addition to healthy lifestyle behaviors such as increased exercise and a calorie-reduced diet

Endocrine Pathology

These new ways of being in the world are deeply rooted. Then she helps her patients slowly wean off the drug over the next four to six months

Semaglutide: widely available, multiple options Semaglutide has the broadest availability of the three

Baseline characteristic and outcomes of CVOTs are listed in Table 2